Pharmafile Logo

patient expectations

- PMLiVE

Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine

Preliminary laboratory studies show both vaccines neutralise Omicron BA.4 and BA.5

- PMLiVE

Bristol Myers Squibb announces positive trial results for treatment of MS

In the two phase 3 trials, Zeposia treatment showed improved or preserved cognitive function in the majority of patients

- PMLiVE

Learning and development: the secret weapon for a successful life science launch

Dave Stuteville, Executive Vice President, Learning & Development, reveals the principles behind successfully training Sales Representatives and Medical Science Liaisons for a rapid biopharmaceutical product launch.

Avalere Health

- PMLiVE

VMLY&R wins two Grand Prix awards at Cannes Lions International Festival of Creativity 2022

The awards were for a first-of-its-kind book for people living with MND, I Will Always Be Me, and mosquito repellent innovation, 'The Killer Pack'

- PMLiVE

Novartis and Precision BioSciences announce in vivo gene editing collaboration

The companies will work together to develop potentially curative treatments for disorders including sickle cell disease and beta thalassaemia

- PMLiVE

Enanta takes legal action against Pfizer over Paxlovid patent infringement

The lawsuit claims the oral COVID-19 antiviral infringes on Enanta’s 11,358,953 patent

- PMLiVE

Sanofi and GSK report positive data for COVID-19 Beta vaccine

Results from stage 1 and stage 2 of the study showed a favourable safety and tolerability profile

- PMLiVE

Pfizer donates $5m in Russian profits to humanitarian causes amid war in Ukraine

The donation will go to eight global and local NGOs to support humanitarian relief and response efforts

- PMLiVE

Delivering content to fuel omnichannel engagement

By Dominic Sloane (pictured below left) and Richard Marshall (pictured below right)

- PMLiVE

Agreeing sustainable value-based contracts with payers: myths and realities

Value-based contracts (VBC) are increasingly considered by companies for many types of therapies. Some companies are suggesting that VBC will become the default for them across their portfolio.

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links